首页> 外国专利> Lipid absorption inhibiting di:hydro-pyridine derivs. - which are 6-amino-4,5-di:aryl-4,5-di:hydro-pyridine-3-carboxylic acid ester(s)

Lipid absorption inhibiting di:hydro-pyridine derivs. - which are 6-amino-4,5-di:aryl-4,5-di:hydro-pyridine-3-carboxylic acid ester(s)

机译:抑制脂质吸收的二:氢吡啶衍生物。 -是6-氨基-4,5-二:芳基-4,5-二:氢吡啶-3-羧酸酯

摘要

New 6-amino-4,5-diaryl-4,5-dihydro pyridine-3-carboxylic acid ester derivs. are the tautomeric cpds. of formula (Ia,b) and their pharmaceutically innocuous salts (where R1 and R2 are aryl or heteroaryl (thienyl, furyl, pyrryl, pyrazolyl, imidazolyl, oxozolyl, isoxazolyl, thiazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, quinolyl, isoquinolyl, indolyl, benzimidazolyl, quinazolyl or quinoxalyl) opt. carrying 1, 2 or 3 substits. selected from phenyl, alkyl, alkenyl, alkynyl, alkoxy, alkenyloxy, alkynyloxy, alkylene, dioxyalkylene, halogen, CF3, OCF3, OH, amino, alkylamino, dialkylamino, alkylarylamino, NO2, CN, N3, COOH, carbalkoxy, carboxamido, sulphonamido and S(O)m-alkyl (m is 0, 1 or 2), the alkyl and alkoxy substituents opt. in turn being substd. by alkoxy, COOH, carbalkoxy, halogen, NH2, alkylamino or dialkylamino; R3 is an open-chain or cyclic, saturated or unsaturated hydrocarbon residue opt. substd. by OH, alkoxy, halogen, aryl or a group -N(R')(R") (in which R' and R" are H, alkyl or aralkyl); and R4 is H, alkyl, aralkyl or a group -N(R"')(R"") (in which R" and R"" are H, aralkyl, alkyl or alkyl substd. by halogen or alkoxy, or -N(R"'(R"") is a 4-to-7-membered aliphatic (sic) ring opt. contg. as a ring member an O- or S-atom or an NH or NR5' group, R5' being a residue as defined for R1 and R2 above)). (Ia,b) have lipid absorption inhibiting activity; in particular, they lower elevated serum cholesterol levels and reduce hypertriglyceridaemia. They are therefore suitable for use in the treatment of hyperlipoproteinoemias, atherosclerosis, adipositas and metabolic disorders induced thereby. (Ia,b) are also useful as diuretics, saluretics, antiarrhythmics and cardiotonics.
机译:衍生出新的6-氨基-4,5-二芳基-4,5-二氢吡啶-3-羧酸酯。是互变异构的cpds。式(Ia,b)的化合物及其药学上无害的盐(其中R 1和R 2是芳基或杂芳基(噻吩基,呋喃基,吡咯基,吡唑基,咪唑基,氧唑基,异恶唑基,噻唑基,吡啶基,哒嗪基,嘧啶基,吡嗪基,喹啉基,喹啉基,吲哚基,苯并咪唑基,喹唑基或喹喔基),带有1,2或3个取代基,选自苯基,烷基,烯基,炔基,烷氧基,烯基氧基,炔基氧基,亚烷基,二氧亚烷基,卤素,CF3,OCF3,OH,氨基,烷基氨基,二烷基氨基,烷基芳基氨基,NO 2,CN,N 3,COOH,碳烷氧基,羧酰胺基,磺酰胺基和S(O)m-烷基(m为0、1或2),烷基和烷氧基取代基依次被烷氧基取代, COOH,烷氧基,卤素,NH 2,烷基氨基或二烷基氨基; R 3是开环或环状的饱和或不饱和烃基,优选由OH,烷氧基,卤素,芳基或-N(R')(R“ )(其中R'和R“是H,烷基或芳烷基);并且R4是H,烷基,芳烷基或-N(R”')(R“”)基团(其中R“和R”“是H ,芳烷基,烷基或烷基取代。 -N(R“'(R”“)是4至7元脂族(sic)环,优选作为O或S原子或NH的环成员NR5'基团,R5'是上面R1和R2所定义的残基))(Ia,b)具有抑制脂质吸收的活性;特别是它们降低了血清胆固醇水平并降低了高甘油三酸酯血症,因此适用于(Ia,b)也可用于治疗高脂蛋白血症,动脉粥样硬化,脂肪沉积和由此引起的代谢紊乱(Ia,b),作为利尿剂,利尿剂,抗心律不齐和强心剂。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号